New York, May 18, 2026, 19:05 EDT
- Nasdaq closed its regular session. As of 19:05 EDT, SBFM traded in Nasdaq’s after-hours slot, which runs 16:00-20:00 ET.
- Sunshine Biopharma finished its last trade at $0.51, up roughly 78%. The stock moved between $0.42 and $2.585 on 436.7 million shares.
- The company set its $6 million public offering at $0.50 a unit. Closing is expected on or about May 19.
Sunshine Biopharma Inc. ($SBFM) stock swung sharply on Monday. The Fort Lauderdale drugmaker set a $6 million public deal at 50 cents a unit. Shares on Nasdaq jumped above the offering price but couldn’t hold those gains, dropping back toward 50 cents as trading stayed busy.
Sunshine’s $6 million gross raise stands out given its size. The company had $6.9 million in cash at March 31 and posted a first-quarter net loss of $1.24 million. That makes the new capital, raised before agent fees and expenses, a significant boost.
The deal could mean a lot of dilution. The offer covers 12 million units, either common or pre-funded, with each unit holding a share or almost a share plus two Series C warrants. The warrants let holders buy extra stock down the road at $0.50 to start. If more shares come out, current shareholders end up with less of the company.
Sunshine’s share count and trading volume point to big swings. As of May 13, the company had 5.0 million common shares outstanding, according to a filing. Monday’s volume was over 436 million shares. That’s possible when the same shares trade over and over, but it’s still a massive number.
Aegis Capital is acting as the exclusive placement agent. The deal is structured as “reasonable best efforts,” so the firm tries to find buyers but does not have to buy or sell any set amount itself.
Sales dropped 9.1% to $8.09 million in the quarter ended March 31, as the company lost some distribution deals. Gross profit slimmed down, and net loss edged higher from last year, according to the company’s latest quarterly filing.
Sunshine sells 60 generic prescription drugs in Canada and plans another 12 launches in 2026. Its proprietary drugs are still early. K1.1 mRNA for liver cancer and SBFM-PL4 for SARS coronavirus infections are both at the animal-testing stage.
April’s report showed 2025 revenue hit $36.3 million. Chief Executive Dr. Steve Slilaty said then the company is still “committed to reaching profitability in the near future.” The financing announced Monday sends more cash to that plan, but the share-count issue is still front and center.
Competition is tough. Sunshine’s annual report says Canada’s generic drug sector has over 35 players, and the top three take around half the market. In antivirals, Sunshine lists Pfizer, Merck and Gilead as major firms with treatments nearby.
SBFM shares jumped while the rest of biotech slid. The SPDR S&P Biotech ETF dropped 2.3% and the iShares Nasdaq Biotechnology ETF shed 1.7% in recent trading. SBFM’s move looked like a company-driven funding trade, not a sector move.
New capital could weigh on the stock. In its first-quarter filing, Sunshine said cash and sales cover 17 months of operations, but it cautioned that estimate may be off. The company also said it has no committed capital lined up and future funding may not come through on terms it likes.
SBFM is set to close Tuesday, with the final prospectus and any new share numbers due after that. As of now, investors have a clear anchor: the deal priced at 50 cents, and SBFM was last seen trading just a penny higher.
